Cash Flow GT Biopharma, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-13.00
-7.00
-20.00
-58.00
-28.00
-38.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
0.00
1.00
-1.00
7.00
2.00
2.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-12.00
-8.00
-15.00
-15.00
-7.00
-3.00
Cash Flow from Investing Activities
12.00
-2.00
12.00
-23.00
0.00
0.00
Cash Flow from Financing Activities
2.00
6.00
0.00
42.00
12.00
3.00
Net Cash Inflow / Outflow
2.00
-4.00
-3.00
3.00
5.00
0.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of GT Biopharma, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-13.162
-24.5340000000431
11.00
46.35%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
0.828
-12.7310000000224
12.00
106.50%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-12.904
-26.770000000047
14.00
51.80%
Cash Flow from Investing Activities
12.893
18.208000000032
-6.00
-29.19%
Cash Flow from Financing Activities
2.976
26.6910000000469
-24.00
-88.85%
Net Cash Inflow / Outflow
2.965
18.0540000000317
-16.00
-83.58%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
-0.0750000000001316
0.00
100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -45.77% vs 41.83% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-12.90
-8.85
-45.77%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
